Skip to main content
. Author manuscript; available in PMC: 2020 Oct 1.
Published in final edited form as: Exp Eye Res. 2019 Aug 23;187:107775. doi: 10.1016/j.exer.2019.107775

Fig. 1. FGF2, but not FGF8 or FGF9, stimulates neovascular sprouting.

Fig. 1.

FGF2 stimulated neovascular sprouting in a dose-dependent manner in C57Bl/6J choroid explants by 8 days post-treatment at doses of 10 or 100 ng/ml (n=9–11; 15.7 ± 1.9 vs. 25.5 ± 7.1 relative sprouting area (RSA) (10ng/mL); *p<0.05, and 15.7 ± 1.9 vs. 38.8 ± 7.4 RSA (100ng/mL); † p<0.01; 2-way mixed ANOVA with Bonferroni’s multiple comparison test). (A). Neither FGF8 (n=14–16; 13.4 ± 0.73 vs. 15.5 ± 1.5 RSA (100ng/mL) (B) nor FGF9 (n=10–14; 13.4 ± 0.73 vs. 18.7 ± 1.5 RSA) (C) stimulated choroidal sprouting regardless of dose. Representative pictures of choroidal explants treated with FGF2, FGF8 or FGF9 (D). Scale bar: 500 μm.